Amgen revenue rose, but '14 sales could slip

Share this article:

Amgen 2013 revenues increased by 17% from 2012 to $18.7 billion, the company reported today. Revenue guidance came in the range of $19.2 to $19.6 billion for 2014.

In its Q4 earnings call today, the Thousand Oaks, CA, biotech also said that evolocumab (AMG-145), the Phase-III PCSK9 antibody it's developing for statin-intolerant patients, would be filed with the FDA in 2014, and SG&A expenses were hiked from $4.8 billion in 2012 to $5.1 billion in 2013.

Barlcays analyst Tony Butler called into question the "sustainability” of the company's revenue growth, given that anemia drugs Epogen and Neupogen and nephrology drug Sensipar will “likely face headwinds in 2014,” given the 2013 expiry of patents for Epogen and Neupogen.

Looking ahead, Amgen expects to have six Phase-III data readouts for drugs in 2014.

Correction: Amgen expects to file evolocumab in 2014.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.